N※N

Zoonotic Viruses Pose Pandemic Threat

  //health-fitness.news-articles.net/content/2026/01/31/zoonotic-viruses-pose-pandemic-threat.html
  Published in Health and Fitness on Saturday, January 31st 2026 at 8:17 GMT by The Independent US
      Locales: THAILAND, CHINA, VIET NAM

Saturday, January 31st, 2026 - Global health experts are raising serious concerns about two zoonotic viruses - Henipavirus and Nipah virus - warning they possess the potential to trigger a pandemic similar in scale to, or even exceeding, the COVID-19 crisis. The viruses, originating in animals, have demonstrated an alarming ability to jump species and cause severe illness in humans, prompting the World Health Organization (WHO) to designate them as "priority diseases" in 2023.

Dr. Thelma Bowman, a global health researcher at George Washington University, emphasizes the gravity of the situation. "The concern is that these viruses have the ability to spread to humans, and they have the potential to cause a pandemic-level event," she stated in a recent interview. "We've learned hard lessons from COVID-19, and we need to apply those lessons now to proactively prepare for these emerging threats."

Understanding the Viruses: Origins and Transmission

Both Henipavirus and Nipah virus belong to the Paramyxoviridae family, though they are not coronaviruses, despite the original report incorrectly labeling them as such. This is a crucial distinction regarding potential vaccine development and treatment strategies. Nipah virus was first identified in Malaysia in 1998 during an outbreak among pig farmers, linked to fruit bats. Henipavirus, specifically the Hendra virus strain, was first identified in 1994 in Australia, also originating in bats and affecting horses and humans. Several distinct strains of Henipavirus have since been discovered across Asia and Africa, highlighting its geographical spread and adaptability.

The primary reservoir for both viruses is believed to be fruit bats, particularly Pteropus species. Transmission to humans often occurs through contact with infected animals - pigs in the case of Nipah, and horses in the case of Hendra Henipavirus. However, human-to-human transmission has also been documented, raising the stakes considerably. Fruit consumption contaminated by bat saliva is another potential, though less common, route of infection. Current research suggests the viruses impact a wide range of animals, increasing their potential to mutate and jump to new hosts.

Symptoms and Severity: A Worrying Resemblance to COVID-19

The symptoms of Henipavirus and Nipah virus infections are concerningly similar to those experienced with COVID-19, initially presenting as fever, cough, and breathing difficulties. However, these viruses often progress to more severe complications, including encephalitis (inflammation of the brain) and seizures. Nipah virus, in particular, carries a significantly higher fatality rate than COVID-19, ranging from 40% to 75% in past outbreaks. Hendra Henipavirus also boasts a high fatality rate, around 57%, though cases are less frequent.

Neurological complications are especially prominent, leading to long-term disabilities in some survivors. Researchers are actively investigating the mechanisms by which these viruses cause such severe neurological damage, with early findings suggesting the viruses attack and destroy neurons directly. The speed of progression from initial symptoms to severe illness is also a critical concern, requiring rapid diagnosis and intervention.

Preparing for the Inevitable: Surveillance, Research, and Prevention

The WHO's inclusion of these viruses on its priority disease list signals the urgent need for increased global preparedness. Dr. Bowman stresses a multi-pronged approach to prevention: "We need to be monitoring animal populations to see if these viruses are becoming more common, and we need to be developing vaccines and treatments to protect humans. We also need to improve our public health infrastructure to ensure that we can quickly respond to any outbreaks."

Currently, there are no licensed vaccines or specific antiviral treatments for either Henipavirus or Nipah virus. However, research is underway to develop both. Efforts are focused on developing broadly neutralizing antibodies and mRNA vaccines, building on the technology successfully used for COVID-19 vaccines. Preliminary trials of a Nipah virus vaccine have shown promising results in animal models, and human trials are planned for late 2026. The challenge lies in the diversity of Henipavirus strains, requiring a potentially complex vaccine strategy.

Beyond vaccine development, enhanced surveillance of both animal and human populations is crucial. This includes monitoring bat populations for viral prevalence, improving biosecurity measures on farms, and establishing rapid diagnostic capabilities in affected regions. International collaboration and data sharing are also essential to track the spread of these viruses and coordinate response efforts. Public awareness campaigns are also vital, educating communities about the risks and preventative measures they can take, such as avoiding contact with bats and properly cooking fruit.